Navigation Links
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Date:8/29/2010

.

About Teriflunomide

Teriflunomide is a new oral disease modifier for RMS that blocks de novo pyrimidine synthesis thus reducing T- and B-cells proliferation with no cytotoxicity. A comprehensive clinical development program for teriflunomide has been launched in monotherapy. First Phase II study results of the safety and efficacy of teriflunomide monotherapy in MS were published in Neurology in 2006. In addition to the TEMSO trial, two other Phase III trials, TOWER and TENERE, are ongoing in RMS. A Phase III study, TOPIC, is also underway in early MS or Clinically Isolated Syndrome (CIS). Teriflunomide has also been evaluated as an adjunct therapy to either interferon 1-beta or glatiramer acetate in two Phase II studies. Results of these studies were presented earlier this year during the American Committee for Treatment and Research in Multiple Sclerosis meeting (ACTRIMS) congress, and the American Academy of Neurology (AAN) meeting respectively. Phase II studies with teriflunomide (7mg and 14mg) in adjunct with interferon 1-beta demonstrated an improvement in outcomes, with a consistent safety profile in patients treated with the adjunct treatment compared with patients treated with IFN-beta and receiving placebo. In the other Phase II study, teriflunomide in adjunct to glatiramer acetate (GA) was well-tolerated compared to patients receiving GA and placebo. Although there was a numerical trend for the reduction in number and volume of gadolinium enhancing T-1 brain MRI lesions in the adjunct arm compared to placebo with GA, the relative effect was not as robust as that observed for teriflunomide with IFN-beta.

About TEMSO Study

TEMSO is a 2-year randomized, double-blind, placebo controlled study including 1088 RMS patients worldwide, aged 18-55 years, with an Expanded Disability Status Scale (EDSS) <= 5.5 and at least one relapse over the previous year or at least 2 relapses over the preceding 2 years. Patients were randomized
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
2. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
3. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
4. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
5. Study Shows Machine Perfusion Significantly Improves Transplant Results
6. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
7. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
8. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
9. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
10. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
11. Buehler Motor, Inc., Significantly Expands Customer and Partner Support in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... SAN CARLOS, Calif. , Aug. 4, 2015 /PRNewswire/ ... non-invasive genetic testing and the analysis of circulating cell-free ... its second quarter ended June 30, 2015 after the ... a conference call and webcast at 1:30 p.m. PT ... activities and financial outlook.Event:Natera,s Second Quarter 2015 Results Conference ...
(Date:8/3/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast ... 2015 on Monday, August 10, 2015 at 4:30 p.m. ... and chief executive officer, will lead the call. On ... for the second quarter 2015. The call ... Halozyme,s corporate website and a recording will be made ...
(Date:8/3/2015)... UK (PRWEB) , ... August 03, 2015 , ... ... consumer of benzene. Benzene is processed to get such derivatives as ethylbenzene, a ... derivatives are principally used within the automotive industry for the production of tyres ...
(Date:8/3/2015)... , August 3, 2015 E-QURE ... commercialization of its Bio-electrical Signal Therapy device ("BST Device"), ... of hard to heal chronic wounds, today announced that ... Chemipal, an Israeli distributor specializing in medical devices, for ... Chemipal is a 70 years old, sales, marketing ...
Breaking Biology Technology:Natera to Release Second Quarter 2015 Results on August 12, 2015 2Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 3E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3
... TE 70, TE 77, TE 70 PWR, TE 77 PWR , ... transfer results using low current and voltage with a minimal amount of buffer. ... with and without built-in power supplies to give maximum flexibility , ... from polyacrylamide gels in less than 1 h , ...
... , ... DIGE Imager • fluorescent Western blotting • multiplex detection • dynamic ... The Ettan™ DIGE Imager is fully compatible with ... and dynamic range as the Typhoon™ scanner. Similar results are also ...
... , Key words: ... Beads, , ... pituitary and are processed into three major peptide hormone fragments: adrenocorticotrophin ... hormones are known to activate the MC 5 (melanocortin subtype ...
Cached Biology Technology:ECL Semi-dry Blotters 2Multiplex protein detection with the ECL Plex fluorescent Western blotting system using the Ettan DIGE Imager 2Multiplex protein detection with the ECL Plex fluorescent Western blotting system using the Ettan DIGE Imager 3Multiplex protein detection with the ECL Plex fluorescent Western blotting system using the Ettan DIGE Imager 4Multiplex protein detection with the ECL Plex fluorescent Western blotting system using the Ettan DIGE Imager 5Multiplex protein detection with the ECL Plex fluorescent Western blotting system using the Ettan DIGE Imager 6Multiplex protein detection with the ECL Plex fluorescent Western blotting system using the Ettan DIGE Imager 7Multiplex protein detection with the ECL Plex fluorescent Western blotting system using the Ettan DIGE Imager 8The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 2The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 3The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 4The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 5
(Date:7/31/2015)... The 10 th International Conference on Genomics ... 22-25, 2015, in Shenzhen , ... 10 th anniversary this year. Since its inauguration in ... annual meetings in the ,omics, fields, and is one of ... ICG-10 focuses on recent breakthroughs and advances in ,omics, ...
(Date:7/27/2015)... 27, 2015   Zynx Health ™, the ... improvement solutions, today announced that its ZynxCarebook ... on Android smartphones and tablets. With this expansion, ... can use ZynxCarebook to securely exchange messages and ... care transitions to other care settings, and improve ...
(Date:7/21/2015)... , July 21, 2015 Today, ZTE ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... FPC1 02 5 for Axon , ...
Breaking Biology News(10 mins):The 10th International Conference on Genomics (ICG-10) to Open in October 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... 29, 2013) Pregnant women with mid to high ... are at risk for having babies with reduced fetal ... in Gastroenterology , the official journal of the ... most commonly found in patients with celiac disease. ...
... April 29, 2013 Research and ... "Gesture Recognition & Touchless Sensing Market (2013 - ... Product (Biometric, Sanitary Equipment); Application (Healthcare, Consumer Electronics, ... to their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ...
... an effective herbal remedy useful for weight control and helping ... ascertain whether green tea truly has this potential, Jae-Hyung Park ... in the Republic of Korea conducted a study, now published ... The active constituents of green tea, which have been ...
Cached Biology News:Pregnant women with high celiac disease antibodies are at risk for low birth weight babies 2Gesture Recognition & Touchless Sensing Market (2013 - 2018): By Technology, Product, Application and Geography 2Gesture Recognition & Touchless Sensing Market (2013 - 2018): By Technology, Product, Application and Geography 3Will green tea help you lose weight? 2
... Coated CELlulose) was developed in the late ... one of the earliest commercial pioneers of ... product range in 1987. Sac-Cel rapidly found ... their own "in house" radioimmunoassays, and became ...
... Our Accumix standard is a new ... mode electrospray ionization mass spectrometry. Accumix ... broad mass range coverage for both tuning ... LCQ- and LTQ-MS) and Fourier transform mass ...
Determin interaction of your protein with Echelons lipids...
... N-Dodecyl-N,N-(dimethylammonio)butyrate White ... properties similar to DDMAU (Cat. No. 252005) ... polymethylene arm. More efficient for the extraction ... than DDMAU. Purity: ≥98% by TLC. ...
Biology Products: